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Taxonomy and Molecular Phylogeny  
 
The classification of Babesia spp. places them in order Piroplasmida, within 
the phylum Apicomplexa.  Babesia spp. are often referred to as piroplasms, a 
collective term for morphologically similar protozoan parasites that utilize 
mammalian erythrocytes in their life cycle.  Piroplasms encompass two main 
genera, Babesia and Theileria; which are currently the subject of intense 
research interest and molecular-based (re-)characterization.  Since babesiosis 
is an emerging disease in many parts of the world, it is very important to 
determine the precise species of the parasite causing the clinical illness and 
the isolate(s) normally present in any given geographical location.  The 
success of treatment may depend on such information since most anti-
babesial drugs have limited efficacy against different Babesia spp.  Similarly, 
inclusion of appropriate antigens into serologic tests is necessary to reduce 
the risk of inaccurate results during screening for diagnostic or 
epidemiological purposes.  The 18S rRNA gene has been favoured for 
molecular phylogenetic studies to date, but others regions of the small subunit 
ribosomal RNA gene, including the first and second transcribed spacers (ITS1 
& ITS2) and 5.8S rRNA gene, and the heat shock protein genes (HSP 70 and 
HSP 90) have also been used, or show promise for future taxonomic studies.   
 
Until recently only two Babesia parasites were thought to occur in dogs; the 
relatively large intra-erythrocytic piroplasm referred to as Babesia canis and a 
smaller parasite, known predominantly as the cause of canine babesiosis in 
Asia, Babesia gibsoni.  Since the late 1980’s “B. canis” has been reclassified 
into three separate species (B. canis, B. rossi and B. vogeli) on the basis of 
cross-immunity, serological testing, vector specificity and molecular phylogeny 
and a new ‘large’ Babesia sp. has been recently described in a dog in North 
Carolina (1). 
 
Molecular characterization of small canine piroplasms has also shed light on 
the classification of these parasites.  Studies, predominantly utilizing the 18S 
rRNA gene locus have revealed that, in general, small canine piroplasms are 
more closely related to Theileria than to Babesia.  These two genera were 
previously separated on the basis of certain life cycle features and 
transovarial passage within the tick vector.  However such historical 
definitions need revisiting in the light of these molecular studies.  To date at 
least 4 genetically and clinically distinct small piroplasms affect dogs which 
include: Babesia gibsoni – originally described in India nearly a century ago 
(2) and now occurring sporadically in other parts of the world including the 
Australia; Babesia conradae, a piroplasm that occasionally infects dogs in 
California (3); Theileria annae, a Babesia microti-like parasite that has so far 
been reported only in northwest Spain, transmitted by Ixodes hexagonus 
(4,5); and a fourth small piroplasm, B. (=T.) equi has also been reported in 
dogs in Spain (6). 
 
Epidemiology of Babesiosis 
 
Babesia Transmission 
It has long been recognised that Babesia spp. can be transmitted by the 
needle passage of infected blood, inadvertently in the case of blood 
transfusions or deliberately during experimental studies.  In general however, 
babesiosis is considered to be a tick-transmitted disease and there have been 
many experiments over the years to elucidate the various tick species that 
fulfil this epidemiological role under natural conditions.  Recent studies 
involving Babesia gibsoni have started to raise some intriguing questions 
about this parasite’s natural mode of transmission.   
 
It is assumed that the initial reports of B. gibsoni infection in countries outside 
Asia (e.g. Australia & USA) were the result of its introduction by (usually 
asymptomatic) carrier dogs travelling from endemic regions.  Recent surveys 
in the USA and our studies in Australia have revealed a high proportion of 
American Staffordshire/Pit Bull Terriers among those dogs with confirmed B. 
gibsoni infection.  In one region of Victoria, 17.5% APBT tested were positive 
for B. gibsoni. Furthermore, these B. gibsoni-positive APBT did not harbour 
any ticks.  Analogous findings have recently been reported in 
thrombocytopenic and anaemic Tosa dogs in northeast Japan, a region that is 
also climatically unfavourable for ticks (7).   The higher prevalence of B. 
gibsoni infection among these particular breeds, renowned for inter-dog 
aggression, suggests that blood exchange, not vector transmission, is the 
main mode of dissemination of B. gibsoni in the USA, Australia and certain 
areas of Japan.  Our epidemiological studies in Victoria revealed that male 
APBT, and those individuals with a history of having bitten, or been bitten by 
other APBT were more likely to have babesiosis.  It is presumed that the 
exposed surfaces of open lacerations in both combatant dogs (infected ‘donor’ 
and ‘recipient’) need to come into intimate contact with each other, and this is 
most likely to occur with injuries inflicted to the head and neck in these 
individuals.  
 
Observations made of these B. gibsoni epizootics may also have implications 
for our understanding of the epidemiology of B. gibsoni infection in endemic 
regions.  Coincidentally, many parts of Asia have large populations of stray 
dogs that roam unhindered throughout urban and rural localities and fighting 
among quarrelsome dogs is inevitable.  Direct dog-to-dog transmission may 
be an important route of infection of B. gibsoni in all localities where it is 
found.  This ‘continual passage’ would limit the opportunities for exchange of 
genetic material for the parasite, since this only occurs during sporogony 
within the tick vector, and the remarkable absence of genetic variation that is 
found between B. gibsoni isolates as geographically distant from each other 
as Sri Lanka, Oklahoma, Malaysia and Okinawa provides further evidence 




Molecular studies of the piroplasms infecting dogs have challenged the 
perception that Babesia spp. are host specific.  It appears that closely related 
piroplasms are capable of infecting several mammalian hosts, a finding that 
may have clinical implications with regard to pathogenicity, diagnosis and 
treatment.  Babesia (=Theileria) equi DNA has been amplified in dogs (6) and 
the Babesia sp. described in North Carolina (1) is closely related to the 
ungulate Babesia species.  The dog from which it was isolated was 
undergoing chemotherapy which suggests that this infection might be 
opportunistic.  It is currently unknown whether this isolate represents a true 
species of dogs, or whether the dog is just an accidental host. 
 
Diagnosis of Babesiosis 
 
Whilst observation of the parasite(s) by light microscopy has long been the 
gold standard test, the genotype of piroplasms cannot be determined by their 
phenotype.  Microscopy is still the only viable option available to veterinarians 
in many parts of the world where babesiosis is endemic but significant 
limitations in its sensitivity and specificity are well recognized.  The 
parasitaemia associated with Babesia is often very low, especially during 
chronic infection, and is easily overlooked.  Failure to detect Babesia 
parasites in animals with haemolytic anaemia or thrombocytopenia has led to 
an incorrect diagnosis in documented cases, often when the clinical suspicion 
of babesiosis was also low.  Given the possibility of direct horizontal 
transmission of canine piroplasms, veterinary clinicians should always 
ascertain whether the patient has been bitten by any other dog in the 
preceding 4-8 weeks, irrespective of its breed. 
 
It is clear that the introduction of PCR has greatly increased the sensitivity of 
parasite detection, yet from a global perspective the routine testing for canine 
babesiosis in this manner is still restricted to very few laboratories.  In very 
early infections, when small numbers of parasites remain at the site of 
inoculation, detection in peripheral blood even by PCR may be unrewarding.  
Of greater clinical significance would be the failure of PCR to detect infection 
in chronic cases.  These carrier dogs are potential sources of infection, 
especially if the right epidemiological conditions exist for transmission.  
Following experimental infection with B. gibsoni we monitored clinical 
parameters, haematology, serologic titre (by IFAT) and the presence of 
Babesia DNA on a daily basis.  All dogs made a full clinical recovery, as 
judged by normal clinical signs, absence of splenic enlargement, a normal 
haemogram and absence of piroplasms on microscopic examination, by 30-50 
days after peak parasitaemia (unpublished results).  During this period of 
clinical normality babesial DNA was inconsistently detected during first-round 
PCR.  Second round PCR improved detection rates but each dog was still 
intermittently negative, yet serological titre was consistently positive.  This 
suggests a very low, fluctuating parasitaemia in these dogs analogous to 
chronic, asymptomatic natural infection.  Serological testing should be used 
concurrently for diagnosis in these dogs but discordant results between PCR 
and IFAT still frustrate efforts to find a perfect testing protocol (8).   
 
The clinical consequences of chronic babesial infection are unclear and while 
most dogs appear to tolerate this state of premunity with few ill effects in our 
experience, theoretically they remain at risk of developing immune-mediated 
complications and recrudescence of clinical disease (and parasitaemia) if 
immunocompromised at a later time.  Chronic infection may be 
inconsequential in some dogs and may be even beneficial for hosts living in 
endemic regions by protecting them from further disease (9), but is an 
unacceptable situation in blood donors or in dogs that are to be exported to 
Babesia-free countries such as New Zealand.  In these latter cases the testing 
protocol must be capable of detecting the carriers with 100% certainty, a 
utopian goal that has yet to be achieved. 
 
Immunofluorescent antibody testing is currently the preferred method of 
serological diagnosis for babesiosis.  As with any serologic assay its major 
diagnostic limitation is the inability to differentiate acute from chronic infection.  
This is of particular relevance to clinicians working in regions that are endemic 
for babesiosis.  In contrast, for B. gibsoni infections in the USA and Australia, 
where the prevalence is generally low in the dog population, the IFAT is a 
useful tool for detection of infected dogs.  Here its application can be 
extended to screening purposes for blood donors and for pre-export testing of 
dogs destined for Babesia-free countries.  Despite the occasional discordant 
result referred to earlier, the combination of IFAT and an appropriately 
controlled PCR seems to hold most promise for achieving optimal diagnostic 
accuracy. 
 
Treatment of Babesiosis 
 
Until recently there has been little change in the options available to 
veterinarians for the treatment of babesiosis in dogs and cats.  Imidocarb 
dipropionate (at 5-6mg/kg IM once, repeated 2 weeks later) and diminazine 
aceturate (3.5mg/kg IN once) have been used extensively in dogs around the 
world in the therapy of large and small babesial infections respectively.  
National therapeutics registration authorities have restricted access to some 
of these drugs in certain countries, including the USA, and some, notably the 
diamidine derivative diminazine, are associated with a high rate of side-
effects.  Other drugs such as doxycycline, clindamycin, quinuronium sulphate, 
trypan blue, pentamidine, phenamidine and parvaquone have all been 
reported with variable degrees of clinical success.  Most, if not all of the drugs 
that have been used to treat babesiosis result in amelioration of clinical signs 
at best and rarely achieve true sterilization of the infection. 
 
The successful treatment of the small piroplasm infections, notably B. gibsoni, 
has been especially challenging.  Based on the close phylogenetic 
relationship between these parasites and Theileria spp., the successful 
therapeutic outcome of a macrolide antibiotic combined with an antiprotozoal 
has been noted in rodent models.  The combined use of azithromycin 
(10mg/kg q24h PO for 10 days) and atovaquone (13.3mg/kg q8h PO for 10 
days) for treating B. gibsoni in dogs is a significant breakthrough that 
combines real clinical efficacy with great safety (10).  Unfortunately the 
expense of the hydroxynapthoquinone component (atovaquone) will reduce 
widespread acceptance of this therapy where it is most needed, in Asia, 
unless the costs can be reduced.  A cheaper formulation of atovaquone with 
proguanil causes an unacceptably high incidence of gastrointestinal side-
effects in dogs.  Despite the undoubted benefits of the atovaquone and 
azithromycin combination for treating B. gibsoni infections, further research is 
needed to determine whether the parasite is truly eliminated.  Data from 
experimental infections in our laboratory and from Japan (11) suggest that a 
low parasitaemia persists as indicated by persistent detection of parasite DNA 
in the blood of some dogs following treatment.  The search for better 
antiprotozoal agents has recently led to the investigation of plant extracts from 
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